Treace Medical Concepts/$TMCI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Treace Medical Concepts
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Ticker
$TMCI
Sector
Primary listing
Employees
477
Headquarters
Website
TMCI Metrics
BasicAdvanced
$456M
-
-$0.79
0.68
-
Price and volume
Market cap
$456M
Beta
0.68
52-week high
$10.79
52-week low
$4.54
Average daily volume
390K
Financial strength
Current ratio
3.523
Quick ratio
2.392
Long term debt to equity
68.525
Total debt to equity
71.807
Interest coverage (TTM)
-9.10%
Profitability
EBITDA (TTM)
-39.41
Gross margin (TTM)
80.12%
Net profit margin (TTM)
-23.01%
Operating margin (TTM)
-22.38%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-13.83%
Return on equity (TTM)
-46.89%
Valuation
Price to revenue (TTM)
2.113
Price to book
4.66
Price to tangible book (TTM)
5.9
Price to free cash flow (TTM)
-15.497
Free cash flow yield (TTM)
-6.45%
Free cash flow per share (TTM)
-0.466
Growth
Revenue change (TTM)
7.67%
Earnings per share change (TTM)
-23.48%
3-year revenue growth (CAGR)
23.28%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about TMCI
Analyst ratings (Buy, Hold, Sell) for Treace Medical Concepts stock.
Bulls say / Bears say
Revenue growth and improved profitability metrics, with second quarter 2025 revenue up 7% year-over-year to $47.4 million and net loss reduced by 18%, show the company building financial momentum. (FT.com)
Expanding the product lineup with full market release of Nanoplasty®, Percuplasty™ 3D MIS osteotomy systems, and SpeedMTP® fusion system positions Treace to gain a larger share of the bunion and midfoot markets. (FT.com)
Peer-reviewed four-year clinical data published in The Journal of Foot & Ankle Surgery differentiate Lapiplasty® as the only commercial bunion system supported by extensive multicenter long-term evidence. (FT.com)
Persistent net losses highlight that the company still faces uncertainty on its path to profitability, with a second quarter 2025 net loss of $17.4 million (-0.28 per share) and an adjusted EBITDA loss of $3.6 million. (FT.com)
High operating expenses continue to exceed gross profit, as second quarter 2025 operating expenses of $54.7 million were above gross profit of $37.8 million, indicating sustained cash burn. (FT.com)
Ongoing patent litigation, including the lawsuit filed June 5, 2025 against Zimmer Biomet, exposes Treace to possible legal costs and management distractions. (FT.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
TMCI Financial Performance
Revenues and expenses
TMCI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Treace Medical Concepts stock?
Treace Medical Concepts (TMCI) has a market cap of $456M as of September 16, 2025.
What is the P/E ratio for Treace Medical Concepts stock?
The price to earnings (P/E) ratio for Treace Medical Concepts (TMCI) stock is 0 as of September 16, 2025.
Does Treace Medical Concepts stock pay dividends?
No, Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Treace Medical Concepts dividend payment date?
Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Treace Medical Concepts?
Treace Medical Concepts (TMCI) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.